Engineered interleukin-2 cytokine compositions and methods of use
Patent Information
- Application Number
- CN202480055166.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-07-13
- Filing Date
- 2024-07-12
- Publication Date
- 2026-10-16
AI Technical Summary
[0004]IL-2已显示出作为抗癌免疫疗法的前景，但功效及安全性被Treg细胞的优先刺激所导致的剂量限制性毒性及IL-2Rα结合所导致的剂量限制性毒性减弱
[0066] This invention provides a method for treating a disease or condition, comprising administering to an individual an effective amount of a polypeptide, nucleic acid, carrier, cell, or pharmaceutical composition as described herein, wherein the severity of signs or symptoms of the disease or condition is reduced, thereby treating the disease or condition. This invention also provides a method for preventing a disease or condition, comprising administering to an individual an effective amount of a polypeptide, nucleic acid, carrier, cell, or pharmaceutical composition as described herein, wherein the onset or recurrence of signs or symptoms of the disease or condition is delayed or inhibited, thereby preventing the disease or condition. In some embodiments, the disease or condition includes cancer or a subtype thereof. In some embodiments, the cancer or its subtype includes liquid cancer. In some embodiments, the cancer or its subtype includes hematologic cancer. In some embodiments, the cancer or its subtype includes solid cancer.